CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management Tirzepitide and Cagrilintide TikTok